TABLE 4.

Differences in the presence of cda, stx2c, and streptomycin, sulfisoxazole, and tetracycline antimicrobial resistance among LSPA6 genotypes

GenotypeaOriginnbPresence ofc:
stx2ccdaStreptomycin, sulfisoxazole, and tetracycline resistance
No. positive% PositiveSSNo. positive% PositiveSSNo. positive% PositiveSS
LSPA6-LIBovine5311.9a1528.3a, c1*1.9a
Human5911.7a1118.6a0*0a
Total11221.8a2623.2a1*0.9a
LSPA6-LI/IIBovine5480b, c120a, b00a, b
Human9333.3b00a00a
Total14750b17.1a00a
LSPA6-LIIBovine494898c2755.1b36†73.5c
Human121191.7b, c433.3a, b8†66.7b, c
Total615996.7c3150.8b, c44†72.1c
  • a LSPA6-LI refers to LSPA6 genotype 111111, LSPA6-LI/II refers to LSPA6 genotype 211111, and LSPA6-LII refers to alllineage II-related LSPA6 genotypes.

  • b  n, Number of samples examined.

  • c Statistical significance (SS) was evaluated at the P < 0.01 level. Test groups of strains with the same letter designation did not have a statistically significant difference in carriage rate for the specific trait (Fisher exact test, P < 0.01), e.g., bovine LSPA6-L1 and human LSPA6-L1 do not have a significant difference in the presence of cda, whereas bovine LSPA6-L1 and bovine LSPA-LII do. For the P values associated with the various pairwise comparisons, please refer to Tables S1, S2, and S3 in the supplemental material. *, one bovine and five human LSPA6-LI strains were resistant to single antibiotics or other combinations of antibiotics other than streptomycin, sulfisoxazole, and tetracycline; †, all LSPA6-LII strains expressing AMR were resistant to streptomycin, sulfisoxazole, and tetracycline.